The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 2 study of an anti–PD-L1 antibody (atezolizumab) in dedifferentiated chondrosarcoma.
 
Mohamad Adham Salkeni
Research Funding - AstraZeneca/MedImmune (Inst); Genentech (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Quintiles Inc. (Inst); Seagen (Inst); Takeda (Inst)
 
Brian Ko
No Relationships to Disclose
 
Brian Andrew Van Tine
Leadership - Polaris
Honoraria - Bionest Partner; Horizon CME; Research to Practice; Targeted Oncology
Consulting or Advisory Role - Adaptimmune; ADRx; Apexigen; Ayala Pharmaceuticals; Bayer; Boehringer Ingelheim; Cytokinetics; Daiihi Sankyo; Deciphera; EcoR1 Capital; EcoR1 Capital; EMD Serono; Epizyme; GlaxoSmithKline; Immune Design; Intellisphere; Lilly; Novartis; Pfizer; PTC Therapeutics
Speakers' Bureau - Adaptimmune; GlaxoSmithKline; Lilly; Novartis
Research Funding - GlaxoSmithKline; Merck; Pfizer; TRACON Pharma
Patents, Royalties, Other Intellectual Property - Accuronix Therapeutics- Licensing agreement. Sigma-2 Receptor Ligands and Therapeutic uses therefor (006766), • Modular Platform for Targeted Therapeutic Delivery (006755), • Sigma-2 Receptor Ligand Drug Conjugates as Antitumor Compounds, Methods of synth; Patent on ALEXT3102; Patent on the use of ME1 as a biomarker
Expert Testimony - Health Advances
Travel, Accommodations, Expenses - Adaptimmune; Advenchen Laboratories; GlaxoSmithKline; Lilly
 
Anthony Paul Conley
Consulting or Advisory Role - AADi; Applied Clinical Intelligence; Bayer; Deciphera; Deciphera; Genentech; Guidepoint Global; InhibRx; Medscape; Nektar; Novartis; OncLive; Schlesinger Associates
Research Funding - Bavarian Nordic (Inst); Chordoma Foundation (Inst); EpicentRx (Inst); Ignyta (Inst); InhibRx (Inst); Iovance Biotherapeutics (Inst); Lilly (Inst); MedImmune (Inst); NantHealth (Inst); NCI (Inst)
Travel, Accommodations, Expenses - Genentech
 
Elizabeth J. Davis
Honoraria - MJH Life Sciences
Consulting or Advisory Role - Aadi; Deciphera
Speakers' Bureau - Physicans' Education Resource
Research Funding - Actuate Therapeutics (Inst); Bristol-Myers Squibb (Inst); Five Prime Therapeutics (Inst); Genentech (Inst); Incyte (Inst); InhibRx (Inst); Karyopharm Therapeutics (Inst); TopAlliance BioSciences Inc (Inst)
 
Melissa Amber Burgess
Consulting or Advisory Role - Rain Therapeutics; SpringWorks Therapeutics
Research Funding - Merck
 
Julia Lee Close
No Relationships to Disclose
 
Jared C. Foster
No Relationships to Disclose
 
Geraldine Helen O'Sullivan Coyne
Travel, Accommodations, Expenses - Novartis Ireland Ltd.
 
Nancy Moore
Patents, Royalties, Other Intellectual Property - Nestle Nutrition
 
Kristin K. Fino
No Relationships to Disclose
 
Katherine V. Ferry-Galow
No Relationships to Disclose
 
Christina Rosenberger
No Relationships to Disclose
 
Ralph E. Parchment
Employment - Leidos Biomedical Research
Stock and Other Ownership Interests - Inovio Pharmaceuticals; Leidos; SciTech Development LLC
Patents, Royalties, Other Intellectual Property - Cambridge University Press for The Biological Basis of Cancer; named inventor on EU patent EP3430051B1; Named Inventor on US Patent 9,644,037; Named inventor on US Patent US8709379 B2
 
Elad Sharon
No Relationships to Disclose
 
James H. Doroshow
No Relationships to Disclose
 
Alice P. Chen
No Relationships to Disclose